Mys­tery in­vestors back a new NASH ap­proach; GSK an­tibi­otics sale trig­gers lay­off fears

A mys­tery in­vestor is back­ing a new late-stage ef­fort to treat NASH, lead­ing an $80 mil­lion crossover round for Sagimet Bio­sciences.

The Se­ries F round was led by an “undis­closed pub­lic eq­ui­ty health­care in­vest­ment fund” and joined by Al­tium Cap­i­tal, HM Cap­i­tal, In­vus, and PFM Health Sci­ences, As­cle­tis, Klein­er Perkins, New En­ter­prise As­so­ciates, and Rock Springs Cap­i­tal. It comes on the heels of pos­i­tive mid-stage da­ta last June, when the com­pa­ny an­nounced a 61% re­sponse rate in 30 pa­tients and a me­di­an liv­er fat re­duc­tion of 28.2%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER